JP2020530296A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530296A5 JP2020530296A5 JP2020507074A JP2020507074A JP2020530296A5 JP 2020530296 A5 JP2020530296 A5 JP 2020530296A5 JP 2020507074 A JP2020507074 A JP 2020507074A JP 2020507074 A JP2020507074 A JP 2020507074A JP 2020530296 A5 JP2020530296 A5 JP 2020530296A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- domain
- item
- fcrn
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims description 83
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 83
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 83
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims description 14
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims description 14
- 238000006467 substitution reaction Methods 0.000 claims description 12
- 108010068617 neonatal Fc receptor Proteins 0.000 claims description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 4
- 235000018102 proteins Nutrition 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Chemical group OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 3
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 2
- 101150013553 CD40 gene Proteins 0.000 claims description 2
- 101150029707 ERBB2 gene Proteins 0.000 claims description 2
- 108010087819 Fc receptors Proteins 0.000 claims description 2
- 102000009109 Fc receptors Human genes 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 claims description 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 2
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 claims description 2
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims description 2
- 108010073807 IgG Receptors Proteins 0.000 claims description 2
- 102100032818 Integrin alpha-4 Human genes 0.000 claims description 2
- 108010041012 Integrin alpha4 Proteins 0.000 claims description 2
- 108010002352 Interleukin-1 Proteins 0.000 claims description 2
- 102000000589 Interleukin-1 Human genes 0.000 claims description 2
- 102000003814 Interleukin-10 Human genes 0.000 claims description 2
- 108090000174 Interleukin-10 Proteins 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- 102000004889 Interleukin-6 Human genes 0.000 claims description 2
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 2
- 108010052285 Membrane Proteins Proteins 0.000 claims description 2
- 102000018697 Membrane Proteins Human genes 0.000 claims description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 2
- 102000014128 RANK Ligand Human genes 0.000 claims description 2
- 108010025832 RANK Ligand Proteins 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 2
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 2
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical group OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 claims 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 238000000034 method Methods 0.000 description 19
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 7
- 230000035772 mutation Effects 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 238000011319 anticancer therapy Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022126967A JP7583767B2 (ja) | 2017-08-11 | 2022-08-09 | 血清中半減期の増強のための操作された抗体ｆｃバリアント |
| JP2024193182A JP2025013474A (ja) | 2017-08-11 | 2024-11-01 | 血清中半減期の増強のための操作された抗体ｆｃバリアント |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762544622P | 2017-08-11 | 2017-08-11 | |
| US62/544,622 | 2017-08-11 | ||
| PCT/US2018/046398 WO2019033087A1 (en) | 2017-08-11 | 2018-08-11 | MODIFIED FC ANTIBODY VARIANTS FOR ENHANCED SERIAL HALF LIFE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022126967A Division JP7583767B2 (ja) | 2017-08-11 | 2022-08-09 | 血清中半減期の増強のための操作された抗体ｆｃバリアント |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020530296A JP2020530296A (ja) | 2020-10-22 |
| JP2020530296A5 true JP2020530296A5 (enExample) | 2021-10-21 |
| JP7191087B2 JP7191087B2 (ja) | 2022-12-16 |
Family
ID=65272701
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020507074A Active JP7191087B2 (ja) | 2017-08-11 | 2018-08-11 | 血清中半減期の増強のための操作された抗体ｆｃバリアント |
| JP2022126967A Active JP7583767B2 (ja) | 2017-08-11 | 2022-08-09 | 血清中半減期の増強のための操作された抗体ｆｃバリアント |
| JP2024193182A Pending JP2025013474A (ja) | 2017-08-11 | 2024-11-01 | 血清中半減期の増強のための操作された抗体ｆｃバリアント |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022126967A Active JP7583767B2 (ja) | 2017-08-11 | 2022-08-09 | 血清中半減期の増強のための操作された抗体ｆｃバリアント |
| JP2024193182A Pending JP2025013474A (ja) | 2017-08-11 | 2024-11-01 | 血清中半減期の増強のための操作された抗体ｆｃバリアント |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US11059892B2 (enExample) |
| EP (1) | EP3665195A4 (enExample) |
| JP (3) | JP7191087B2 (enExample) |
| KR (1) | KR102867311B1 (enExample) |
| CN (1) | CN111032688A (enExample) |
| AU (1) | AU2018314257B2 (enExample) |
| CA (1) | CA3072099A1 (enExample) |
| IL (1) | IL272561B2 (enExample) |
| WO (1) | WO2019033087A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4017529A4 (en) * | 2019-08-22 | 2024-03-13 | Cidara Therapeutics, Inc. | FIELDS FC VARIANTS AND THEIR USES |
| EP4225787A4 (en) * | 2020-05-21 | 2024-10-23 | Zydus Lifesciences Limited | FC VARIANT AND PRODUCTION THEREOF |
| JP7659628B2 (ja) * | 2020-11-11 | 2025-04-09 | ギリアード サイエンシーズ， インコーポレイテッド | ｇｐ１２０ ＣＤ４結合部位指向性抗体による治療に感受性のＨＩＶ患者を特定する方法 |
| KR20230152032A (ko) | 2021-02-03 | 2023-11-02 | 모차르트 쎄라퓨틱스 인코포레이티드 | 결합제 및 이를 사용하는 방법 |
| EP4319820A1 (en) | 2021-04-10 | 2024-02-14 | Profoundbio Us Co. | Folr1 binding agents, conjugates thereof and methods of using the same |
| JP7742892B2 (ja) | 2021-04-23 | 2025-09-22 | ジェンマブ エー／エス | 抗ｃｄ７０抗体、そのコンジュゲートおよびこれを使用する方法 |
| TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| US20250188186A1 (en) * | 2021-12-10 | 2025-06-12 | Board Of Regents, The University Of Texas System | Ph-selective antibody fc domains |
| WO2024030956A2 (en) | 2022-08-03 | 2024-02-08 | Mozart Therapeutics, Inc. | Cd39-specific binding agents and methods of using the same |
| WO2024044477A1 (en) | 2022-08-26 | 2024-02-29 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
| CN121194993A (zh) | 2023-05-24 | 2025-12-23 | 莫扎特治疗公司 | Cd8特异性结合蛋白及其应用方法 |
| TW202509078A (zh) | 2023-07-07 | 2025-03-01 | 美商維里迪恩醫療股份有限公司 | 治療慢性甲狀腺眼病之方法 |
| WO2025072406A1 (en) | 2023-09-26 | 2025-04-03 | Profoundbio Us Co. | Ptk7 binding agents, conjugates thereof and methods of using the same |
| WO2025117639A1 (en) | 2023-11-27 | 2025-06-05 | Profoundbio Us Co. | Antibodies and methods for ptk7 detection |
| TW202547866A (zh) | 2024-01-10 | 2025-12-16 | 丹麥商珍美寶股份有限公司 | Ｓｌｉｔｒｋ６結合劑、其共軛物及使用彼之方法 |
| WO2025170982A2 (en) | 2024-02-06 | 2025-08-14 | Paragon Therapeutics, Inc. | Il-23 antibody compositions and methods of use |
| WO2025171006A1 (en) * | 2024-02-06 | 2025-08-14 | Paragon Therapeutics, Inc. | Il-23 binding protein compositions and methods of use |
| US20250381289A1 (en) | 2024-02-29 | 2025-12-18 | Genmab A/S | Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same |
| WO2025222129A2 (en) | 2024-04-19 | 2025-10-23 | Mozart Therapeutics, Inc. | Engineered cytokines and targeted cytokine delivery |
| WO2026090160A2 (en) | 2024-10-22 | 2026-04-30 | Gilead Sciences, Inc. | Cd4-targeted il-15 molecules and methods of use |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
| US4870287A (en) | 1988-03-03 | 1989-09-26 | Loma Linda University Medical Center | Multi-station proton beam therapy system |
| US5801029A (en) | 1993-02-16 | 1998-09-01 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
| GB9506466D0 (en) | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
| US5702892A (en) | 1995-05-09 | 1997-12-30 | The United States Of America As Represented By The Department Of Health And Human Services | Phage-display of immunoglobulin heavy chain libraries |
| US5760395A (en) | 1996-04-18 | 1998-06-02 | Universities Research Assoc., Inc. | Method and apparatus for laser-controlled proton beam radiology |
| US5739169A (en) | 1996-05-31 | 1998-04-14 | Procept, Incorporated | Aromatic compounds for inhibiting immune response |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7094571B2 (en) | 2000-10-27 | 2006-08-22 | The Board Of Regents Of The University Of Texas System | Combinatorial protein library screening by periplasmic expression |
| US7419783B2 (en) | 2001-11-05 | 2008-09-02 | Research Development Foundation | Engineering of leader peptides for the secretion of recombinant proteins in bacteria |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| JP2005520569A (ja) | 2002-03-23 | 2005-07-14 | リサーチ ディベロップメント ファンデーション | バクテリア内で複数のジスルフィド結合を有する蛋白質の分泌とその利用 |
| US7611866B2 (en) | 2002-07-15 | 2009-11-03 | Board Of Regents, The University Of Texas System | Selection of bacterial inner-membrane anchor polypeptides |
| US9051373B2 (en) * | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
| EP2385069A3 (en) | 2003-11-12 | 2012-05-30 | Biogen Idec MA Inc. | Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto |
| WO2007024249A2 (en) | 2004-11-10 | 2007-03-01 | Macrogenics, Inc. | Engineering fc antibody regions to confer effector function |
| US8546543B2 (en) * | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| BRPI0517837A (pt) | 2004-11-12 | 2008-10-21 | Xencor Inc | variantes fc com ligação alterada a fcrn |
| CA2595169A1 (en) | 2005-01-12 | 2006-07-20 | Xencor, Inc. | Antibodies and fc fusion proteins with altered immunogenicity |
| WO2008106982A2 (en) | 2007-03-07 | 2008-09-12 | Aarhus Universitet | Pig model for atherosclerosis |
| DK2155789T3 (da) | 2007-05-01 | 2013-10-21 | Res Dev Foundation | Immunoglobulin-Fc-biblioteker |
| US8043621B2 (en) | 2007-05-10 | 2011-10-25 | Ramot At Tel Aviv University Ltd. | Recombinant fusion protein and polynucleotide construct for immunotoxin production |
| CN102549016B (zh) | 2009-06-30 | 2015-05-06 | 研究发展基金会 | 免疫球蛋白fc多肽 |
| TWI667257B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體 |
| GB201112429D0 (en) * | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
| US20150050269A1 (en) | 2011-09-30 | 2015-02-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
| TW201817744A (zh) * | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| CN104010659A (zh) | 2011-12-19 | 2014-08-27 | 洛克菲勒大学 | 非唾液酸化的抗炎多肽 |
| EP3892638A1 (en) * | 2012-05-30 | 2021-10-13 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for eliminating aggregated antigens |
| EP3142700B1 (en) * | 2014-05-16 | 2021-03-03 | Medimmune, LLC | Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties |
| JP6034332B2 (ja) | 2014-05-30 | 2016-11-30 | トヨタ自動車株式会社 | 組換え微生物及び当該組換え微生物を用いた物質製造方法 |
| EP3215528B1 (en) * | 2014-11-06 | 2019-08-07 | F.Hoffmann-La Roche Ag | Fc-region variants with modified fcrn-binding and methods of use |
| TWI901940B (zh) | 2017-08-03 | 2025-10-21 | 美商安進公司 | 介白素-21突變蛋白及治療方法 |
-
2018
- 2018-08-11 JP JP2020507074A patent/JP7191087B2/ja active Active
- 2018-08-11 AU AU2018314257A patent/AU2018314257B2/en active Active
- 2018-08-11 KR KR1020207004453A patent/KR102867311B1/ko active Active
- 2018-08-11 CA CA3072099A patent/CA3072099A1/en active Pending
- 2018-08-11 US US16/101,421 patent/US11059892B2/en active Active
- 2018-08-11 EP EP18844094.5A patent/EP3665195A4/en active Pending
- 2018-08-11 IL IL272561A patent/IL272561B2/en unknown
- 2018-08-11 CN CN201880051999.9A patent/CN111032688A/zh active Pending
- 2018-08-11 WO PCT/US2018/046398 patent/WO2019033087A1/en not_active Ceased
-
2021
- 2021-06-14 US US17/346,648 patent/US11958904B2/en active Active
-
2022
- 2022-08-09 JP JP2022126967A patent/JP7583767B2/ja active Active
-
2024
- 2024-04-05 US US18/628,078 patent/US20240270852A1/en active Pending
- 2024-11-01 JP JP2024193182A patent/JP2025013474A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114401997B (zh) | 细胞因子前药和双前药 | |
| CN109641049B (zh) | Cd3结合抗体 | |
| WO2021035188A1 (en) | Novel il-21 prodrugs and methods of use thereof | |
| US20250051413A1 (en) | Chimeric molecules comprising il-12 agonist polypeptide | |
| TWI831789B (zh) | 二聚體及其用途 | |
| US20150056183A9 (en) | Therapeutic canine immunoglobulins and methods of using same | |
| KR102627471B1 (ko) | 조작된 항-il-2 항체 | |
| WO2022155541A1 (en) | Interferon prodrugs and methods of making and using the same | |
| CN114044827B (zh) | 低adcc/cdc功能性单抗及其制备方法与应用 | |
| US11680102B2 (en) | Anti-BAFF receptor antibodies and uses thereof | |
| US20210261654A1 (en) | Anti-il-17 antibody/tnfr ecd fusion protein and use thereof | |
| CN110612309A (zh) | 用于降低免疫原性的方法和组合物 | |
| KR20250028265A (ko) | 항체 및 이의 용도 | |
| US20260098090A1 (en) | Fusions with cd8 antigen binding molecules for treating chronic viral infection | |
| CN118909108A (zh) | 靶向atrn蛋白的抗体或其抗原结合片段及其应用 | |
| KR20250117442A (ko) | TNF-α 및 IL-17A를 표적하는 이중특이적 융합 단백질 및 이의 용도 | |
| WO2024017281A1 (zh) | 多特异性抗体及其用途 | |
| Colwill et al. | Optimising monoclonal antibody drug development for inflammatory bowel disease | |
| JP2024534257A (ja) | 二重特異性組換えタンパク質及びその使用 | |
| TW202330027A (zh) | 抗ｃｄ－４７抗體製劑 | |
| WO2025119304A1 (en) | Heterodimeric proteins against il-12 receptor | |
| RU2829156C2 (ru) | Композиция, содержащая анти-pd-1/her2 биспецифическое антитело, способ ее получения и ее использование | |
| KR102962557B1 (ko) | 새로운 il-15 프로드럭 및 이를 사용하는 방법 | |
| WO2025221933A9 (en) | Antibodies and polypeptides comprising variant fc regions | |
| CN117279942A (zh) | 用于治疗疼痛的化合物和方法 |